Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a ...

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 /PRNewswire/ -- Ouro Medicines, a clinical stage biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated ...

Detailed price information for Casi Pharmaceuticals Inc (CASI-Q) from The Globe and Mail including charting and trades.

Detailed price information for Casi Pharmaceuticals Inc (CASI-Q) from The Globe and Mail including charting and trades.

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet ...

Although the exact incidence of IMHA in dogs is unknown, it’s considered one of the most common autoimmune conditions faced by our canine companions. Because the condition is potentially deadly, pet ...

Primary immune thrombocytopenia (ITP) is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting, which can lead to life-threatening ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to second-line eltrombopag prolonged time to treatment failure by more than 40%. Researchers ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...